AU2022312760A1 - Use of lactobacillus paracasei bacterial strains in the treatment of newborns - Google Patents

Use of lactobacillus paracasei bacterial strains in the treatment of newborns Download PDF

Info

Publication number
AU2022312760A1
AU2022312760A1 AU2022312760A AU2022312760A AU2022312760A1 AU 2022312760 A1 AU2022312760 A1 AU 2022312760A1 AU 2022312760 A AU2022312760 A AU 2022312760A AU 2022312760 A AU2022312760 A AU 2022312760A AU 2022312760 A1 AU2022312760 A1 AU 2022312760A1
Authority
AU
Australia
Prior art keywords
group
strain
bacteria
mixture
lactobacillus paracasei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022312760A
Other languages
English (en)
Inventor
Andrea BIFFI
Walter FIORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of AU2022312760A1 publication Critical patent/AU2022312760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022312760A 2021-07-15 2022-07-15 Use of lactobacillus paracasei bacterial strains in the treatment of newborns Pending AU2022312760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000018740 2021-07-15
IT102021000018740A IT202100018740A1 (it) 2021-07-15 2021-07-15 Uso di ceppi di batteri Lactobacillus paracasei nel trattamento di neonati
PCT/IB2022/056538 WO2023286027A1 (en) 2021-07-15 2022-07-15 Use of lactobacillus paracasei bacterial strains in the treatment of newborns

Publications (1)

Publication Number Publication Date
AU2022312760A1 true AU2022312760A1 (en) 2024-02-22

Family

ID=78212428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022312760A Pending AU2022312760A1 (en) 2021-07-15 2022-07-15 Use of lactobacillus paracasei bacterial strains in the treatment of newborns

Country Status (11)

Country Link
US (1) US20240350567A1 (https=)
EP (1) EP4370142A1 (https=)
JP (1) JP2024525794A (https=)
KR (1) KR20240038015A (https=)
CN (1) CN119365205A (https=)
AU (1) AU2022312760A1 (https=)
CA (1) CA3222905A1 (https=)
IL (1) IL309883A (https=)
IT (1) IT202100018740A1 (https=)
MX (1) MX2024000520A (https=)
WO (1) WO2023286027A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118813489A (zh) * 2024-08-29 2024-10-22 北京科拓恒通生物技术股份有限公司 一种用于缓解便秘和腹泻的益生菌后生元和制备方法及其用途
CN120361059A (zh) * 2025-06-30 2025-07-25 天津创源生物技术有限公司 一种副干酪乳酪杆菌iob413后生元在胃食管反流上的应用
CN121533530A (zh) * 2026-01-19 2026-02-17 内蒙古农业大学 一种副干酪乳酪杆菌-复合益生元复配制剂、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
IT201900000801A1 (it) * 2019-01-18 2020-07-18 Proge Farm Srl Composizione comprendente batteri probiotici non vitali e suo uso in terapia
IT201900016865A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016811A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900020422A1 (it) * 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
IT202000012448A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
IT202100008300A1 (it) * 2021-04-01 2022-10-01 Bll Invest S R L Ceppi di batteri inattivati, quali batteri vitali ma non coltivabili, loro composizioni e loro uso

Also Published As

Publication number Publication date
US20240350567A1 (en) 2024-10-24
WO2023286027A1 (en) 2023-01-19
KR20240038015A (ko) 2024-03-22
IL309883A (en) 2024-03-01
CA3222905A1 (en) 2023-01-19
IT202100018740A1 (it) 2023-01-15
JP2024525794A (ja) 2024-07-12
CN119365205A (zh) 2025-01-24
MX2024000520A (es) 2024-01-31
EP4370142A1 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
US20210106629A1 (en) Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
US10155015B2 (en) Probiotic compositions for use in the treatment of bowel diseases
US20240350567A1 (en) Use of lactobacillus paracasei bacterial strains in the treatment of newborns
Power et al. Intestinal microbiota, diet and health
CA2752800C (en) Prebiotic formulations and methods of use
US20220325234A1 (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
EP4548775A2 (en) Gold kiwifruit compositions and methods of preparation and use therefor
WO2018175879A1 (en) Methods of treating lactose intolerance and improving gastrointestinal health
EP3986163A2 (en) Microbial compositions and methods for producing upgraded probiotic assemblages
CA3031002A1 (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
CN120607980A (zh) 菌株和组合物
KR20240093392A (ko) 질병 치료를 위한 조성물 및 방법
CN114615971A (zh) 包含细菌菌株的组合物
US20250170194A1 (en) Microbial compositions and methods for producing upgraded probiotic assemblages
Bashir et al. Human microbiome: Implication of age and external factors
JPWO2023286027A5 (https=)
WO2019113023A9 (en) Probiotics and methods of use
EA053058B1 (ru) Применение бактериальных штаммов lactobacillus paracasei для лечения новорожденных
DK202430232A1 (en) Nutritional composition comprising bifidobacterium bifidum r0071 and human milk oligosaccharides
Fehlbaum Investigation of microbial interactions of Lactobacillus paracasei CNCM I-1518 with elderly gut microbiota and Clostridium difficile using advanced intestinal fermentation models